5F-CUMYL-PINACA
5F-CUMYL-PINACA (also known as SGT-25 and sometimes sold in e-cigarette form as C-Liquid) is an indazole-3-carboxamide based synthetic cannabinoid. 5F-CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with the original patent claiming approximately 4x selectivity for CB, having an EC of <0.1 nM for human CB receptors and 0.37 nM for human CB receptors. In more recent assays using different techniques, 5F-CUMYL-PINACA was variously found to have an EC of 0.43 nM at CB and 11.3 nM at CB, suggesting a somewhat higher CB selectivity  of 26 times, or alternatively 15.1 nM at CB and 34.8 nM at CB with only 2.3 times selectivity, however these figures cannot be directly compared due to the different assay techniques used in each case. Legal status. In the United States, 5F-CUMYL-PINACA was temporarily emergency scheduled by the DEA in 2019. and made a permanent Schedule I Controlled Substance on April 7, 2022. Sweden's public health agency suggested classifying 5F-CUMYL-PINACA as a hazardous substance on November 10, 2014.